Notice: Our website will be down for maintenance from June 13 - June 14.

uniQure Announces Closing of Commercialization and License Agreement with CSL Behring

Read the original press release here uniQure, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the global licensing agreement with CSL Behring for etranacogene dezaparvovec, an investigational gene therapy for patients with hemophilia B, expired […]

en_USEnglish